报告:逾七成中国企业高管疫情后对中国医疗系统评价更正面

2020-07-17 中国新闻网 中国新闻网

《后疫情时代的信心和转变——中国企业高管调研报告》15日在北京发布。报告显示,疫情期间七成中国企业高管经历过生理或精神健康问题,但仅8.7%的人会寻求专业帮助。主办方供图

报告:逾七成中国企业高管疫情后对中国医疗系统评价更正面

《后疫情时代的信心和转变——中国企业高管调研报告》15日在北京发布。报告显示,疫情期间七成中国企业高管经历过生理或精神健康问题,但仅8.7%的人会寻求专业帮助。主办方供图

中新网北京7月15日电 (记者 李亚南)《后疫情时代的信心和转变——中国企业高管调研报告》15日在北京发布。报告显示,疫情期间七成中国企业高管经历过生理或精神健康问题,但仅8.7%的人会寻求专业帮助。经历新冠肺炎疫情后,71.5%的中国企业高管对中国医疗系统的整体看法更正面;56.9%的高管对中国经济发展表示乐观,但疫情发展的不确定性仍然是他们目前最大的担忧。

随着中国疫情进入常态化阶段,企业高级管理人员的身心健康状况和情绪的调适也成为后疫情时期企业保持良好运作的重要因素。有鉴于此,保柏环球(Bupa Global)展开了一项针对中国企业高管的调研活动,旨在更好地了解受新冠肺炎疫情影响,他们对自身健康的关注度,对不同医疗体系的态度,对医疗保险的期待,以及他们对世界和中国宏观经济的看法。本次调研活动收集了中国一二线城市各行各业1031名高级管理人员的反馈。

心理健康成为疫情常态化后值得关注的问题

报告显示,在疫情暴发时,七成中国高管都经历过生理或精神的问题——主要为生活乏味、持续低落、焦虑,甚至是精神疲惫、心力交瘁。但是,仅有8.7%的人会向医护人士、心理咨询师或精神科医生寻求专业帮助。

疫情进入常态化后,虽然高级管理人员对家人和自身健康安全、患上传染病等方面的担忧已经有所减少,但生活习惯已经产生了长远的改变。疫情给高管们带来的五大改变分别是:1)提高个人卫生意识和改善个人卫生习惯;2)健康饮食并更有规律地运动;3)在人多繁杂的地方会提高警觉;4)更注重保持个人心理健康;5)花更多时间陪伴家人和朋友。其中近五成高管更注重个人心理健康,反映高端人士保持心理健康意识的提升。

对于中国经济前景表示乐观,而对于全球经济相对悲观

报告中的另一主要发现是,56.9%的企业高管们对中国经济发展表示乐观。他们认为国内经济会很快复苏,与疫情前一样强势发展甚至更强,但是仍有六成以上的企业高管对疫情发展的不确定性和潜在的经济衰退表示担忧。约四成企业高管对全球经济复苏相对悲观,认为疫情会对全球经济产生持续性影响。

报告显示,重大疾病及住院、及对流行病的保障需求同时位居自费和公司医保需求首两位。对于公司医疗保险的需求中,提供线上/虚拟医生诊症服务跻身前五位。主办方供图

报告显示,重大疾病及住院、及对流行病的保障需求同时位居自费和公司医保需求首两位。对于公司医疗保险的需求中,提供线上/虚拟医生诊症服务跻身前五位。主办方供图

对医疗系统评价更正面,对远程诊疗和精神健康的关注度上升

此外,经历新冠肺炎疫情后,71.5%的中国高管对中国医疗系统的整体看法更正面;53.5%对公立医疗系统的评价比以前更好。因此,保柏环球预测,高管人士对国内公立医疗系统信任度高,对贵宾体验的保险需求将继续增加。

此外,在政府鼓励人们购买商业医疗健康保险的大环境下,大众对自费私人医保购买意愿有增加趋势。高管对于自费医保和公司医保的需求也充分反映了后疫情时代的特点。重大疾病及住院、及对流行病的保障需求同时位居自费和公司医保需求首两位。另外首五位中也发现,高管更关注预防性治疗保障,期望得到更高的保障总额。而对于公司医疗保险的需求中,提供线上/虚拟医生诊症服务跻身前五位,精神健康支持例如心理学家或精神科医生的诊疗保障的需求自疫情暴发以来呈明显增加态势。(完)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951259, encodeId=226d1951259db, content=<a href='/topic/show?id=176a3512324' target=_blank style='color:#2F92EE;'>#医疗系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35123, encryptionId=176a3512324, topicName=医疗系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Aug 01 10:27:15 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722831, encodeId=833d1e2283125, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Tue Jul 28 06:27:15 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444636, encodeId=70a514446363e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456310, encodeId=86511456310c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951259, encodeId=226d1951259db, content=<a href='/topic/show?id=176a3512324' target=_blank style='color:#2F92EE;'>#医疗系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35123, encryptionId=176a3512324, topicName=医疗系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Aug 01 10:27:15 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722831, encodeId=833d1e2283125, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Tue Jul 28 06:27:15 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444636, encodeId=70a514446363e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456310, encodeId=86511456310c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951259, encodeId=226d1951259db, content=<a href='/topic/show?id=176a3512324' target=_blank style='color:#2F92EE;'>#医疗系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35123, encryptionId=176a3512324, topicName=医疗系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Aug 01 10:27:15 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722831, encodeId=833d1e2283125, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Tue Jul 28 06:27:15 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444636, encodeId=70a514446363e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456310, encodeId=86511456310c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951259, encodeId=226d1951259db, content=<a href='/topic/show?id=176a3512324' target=_blank style='color:#2F92EE;'>#医疗系统#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35123, encryptionId=176a3512324, topicName=医疗系统)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Sat Aug 01 10:27:15 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722831, encodeId=833d1e2283125, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Tue Jul 28 06:27:15 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444636, encodeId=70a514446363e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456310, encodeId=86511456310c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jul 19 09:27:15 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 hyf030